Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Mar 2023 07:00 AM
RNS
Notice of Preliminary Results
13 Mar 2023 11:33 AM
RNS
OXB confirms no exposure to SVB receivership
01 Mar 2023 11:16 AM
RNS
Total Voting Rights
20 Feb 2023 07:00 AM
RNS
Dr Frank Mathias to join as new CEO on 27 March
01 Feb 2023 10:18 AM
RNS
Total Voting Rights
27 Jan 2023 07:00 AM
RNS
Board Change
03 Jan 2023 05:19 PM
RNS
Block listing return
03 Jan 2023 11:28 AM
RNS
Total Voting Rights
21 Dec 2022 12:00 PM
RNS
Oxford Biomedica to Present at J.P Morgan
14 Dec 2022 07:00 AM
RNS
Oxford Biomedica Solutions forms new partnerships
22 Nov 2022 07:00 AM
RNS
Oxford Biomedica Appoints Frank Mathias as CEO
15 Nov 2022 02:35 PM
RNS
Holding(s) in Company
14 Nov 2022 07:00 AM
RNS
Sale and leaseback of Windrush Court facility
01 Nov 2022 09:14 AM
RNS
Total Voting Rights
14 Oct 2022 02:28 PM
RNS
PDMR Dealings
12 Oct 2022 07:00 AM
RNS
PDMR Dealings
12 Oct 2022 07:00 AM
RNS
PDMR Dealings
07 Oct 2022 01:16 PM
RNS
PDMR Dealing Amendment
07 Oct 2022 12:28 PM
RNS
PDMR Dealing
07 Oct 2022 07:00 AM
RNS
Amendment of Short-Term Loan Facility
03 Oct 2022 09:34 AM
RNS
Total Voting Rights
15 Sep 2022 07:00 AM
RNS
Interim Results
14 Sep 2022 07:00 AM
RNS
Oxford Biomedica Solutions signs new partner
07 Sep 2022 07:00 AM
RNS
Licence & Supply Agreement with New Partner
01 Sep 2022 09:51 AM
RNS
Total Voting Rights
25 Aug 2022 07:00 AM
RNS
Notice of Interim Results
16 Aug 2022 07:00 AM
RNS
Oxford Biomedica Notes Homology Q2 Report
01 Aug 2022 09:42 AM
RNS
Total Voting Rights
27 Jul 2022 07:00 AM
RNS
Appointment of Joint Corporate Broker
26 Jul 2022 07:00 AM
RNS
Licence & Supply Agreement with New Partner
26 Jul 2022 07:00 AM
RNS
New Project with Orchard Therapeutics
21 Jul 2022 07:00 AM
RNS
Expanded Agreement with BMS's Juno in CAR-T
15 Jul 2022 10:13 AM
RNS
BLOCK LISTING RETURN
01 Jul 2022 09:55 AM
RNS
Total Voting Rights
01 Jul 2022 07:00 AM
RNS
Signs new agreement with AstraZeneca
14 Jun 2022 07:00 AM
RNS
Notes FDA lift clinical hold on pheNIX trial
01 Jun 2022 07:00 AM
RNS
Total Voting Rights
27 May 2022 06:03 PM
RNS
Result of AGM
03 May 2022 05:18 PM
RNS
Grant of options
03 May 2022 04:46 PM
RNS
Director/PDMR Shareholding
03 May 2022 10:35 AM
RNS
Total Voting Rights
29 Apr 2022 05:42 PM
RNS
Directors Dealings / Market Share Purchases
28 Apr 2022 02:24 PM
RNS
Director/PDMR Shareholding
27 Apr 2022 02:58 PM
RNS
2021 Annual report and accounts & AGM notification
27 Apr 2022 12:10 PM
RNS
PDMR Dealings / Market Share Purchase
21 Apr 2022 04:41 PM
RNS
Director Share Purchase
21 Apr 2022 01:24 PM
RNS
Directors Dealings / Market Share Purchase
21 Apr 2022 10:16 AM
RNS
Director/PDMR Shareholding
20 Apr 2022 03:45 PM
RNS
Director/PDMR Shareholding
20 Apr 2022 07:00 AM
RNS
Preliminary Results

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100

Latest directors dealings